![]() |
|
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
|
|
Synonyms | MENT; 7α-Methylnandrolone; 7α-methyl-19-nortestosterone; 17β-hydroxy-7α-methylestr-4-en-3-one |
CAS Number |
3764-87-2 ![]() |
PubChem (CID) | 9838899 |
ChemSpider |
8014619 ![]() |
UNII |
40P3287I94 ![]() |
ECHA InfoCard | 100.184.887 |
Chemical and physical data | |
Formula | C19H28O2 |
Molar mass | 288.424 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
![]() ![]() |
Trestolone (INN), also known as 7α-methyl-19-nortestosterone (MENT) or 7α-methylestr-4-en-17β-ol-3-one, is a synthetic androgenic-anabolic steroid (AAS). It is used to build muscle rapidly and is a theoretical candidate drug for use in hormonal male contraceptive methods. In males, regular administration of sufficient quantities of trestolone induces a reversible state of infertility. Trestolone is used as the acetate ester, trestolone acetate, which is administered via intramuscular injection and acts as a long-lasting prodrug of trestolone.
Trestolone is an experimental contraceptive treatment and is not yet available commercially. It is currently being evaluated for safety and effectiveness in scientific studies, supported by the Population Council.
As a derivative of the anabolic steroid hormone nandrolone (19-nortestosterone), trestolone's viability as a male contraceptive via spermatogenesis suppression is ten-fold in comparison to testosterone.
Spermatozoa are produced in the testes of males in a process called spermatogenesis. In order to render a man infertile, a hormone-based male contraceptive method must stop spermatogenesis by interrupting the release of gonadotropins from the pituitary gland. Even in low concentrations, trestolone is a potent inhibitor of the release of the gonadotropin hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH).